|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0024305,
umls-concept:C0030705,
umls-concept:C0031327,
umls-concept:C0054946,
umls-concept:C0205460,
umls-concept:C0220825,
umls-concept:C0393022,
umls-concept:C0871161,
umls-concept:C1280500,
umls-concept:C1417326,
umls-concept:C1446409,
umls-concept:C1706319
|
|
pubmed:issue |
1-2
|
|
pubmed:dateCreated |
2011-5-11
|
|
pubmed:abstractText |
To report the pharmacokinetics of ¹³¹I-rituximab a patient with a CD20 positive non-Hodgkin Lymphoma who has received ¹³¹I-rituximab as consolidation treatment after remission induction and to evaluate the effect of radioiodination on the biological properties of rituximab.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
1875-869X
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
20
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
37-40
|
|
pubmed:meshHeading |
pubmed-meshheading:21558622-Aged,
pubmed-meshheading:21558622-Antibodies, Monoclonal,
pubmed-meshheading:21558622-Antibodies, Monoclonal, Murine-Derived,
pubmed-meshheading:21558622-Antigens, CD20,
pubmed-meshheading:21558622-Antineoplastic Agents,
pubmed-meshheading:21558622-B-Lymphocytes,
pubmed-meshheading:21558622-Drug Administration Schedule,
pubmed-meshheading:21558622-Half-Life,
pubmed-meshheading:21558622-Humans,
pubmed-meshheading:21558622-Iodine Radioisotopes,
pubmed-meshheading:21558622-Isotope Labeling,
pubmed-meshheading:21558622-Lymphoma, Non-Hodgkin,
pubmed-meshheading:21558622-Male,
pubmed-meshheading:21558622-Positron-Emission Tomography,
pubmed-meshheading:21558622-Radioimmunotherapy,
pubmed-meshheading:21558622-Recurrence,
pubmed-meshheading:21558622-Remission Induction,
pubmed-meshheading:21558622-Tissue Distribution,
pubmed-meshheading:21558622-Treatment Outcome,
pubmed-meshheading:21558622-Whole Body Imaging
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
The pharmacokinetics of ¹³¹I-rituximab in a patient with CD20 positive non-Hodgkin Lymphoma: evaluation of the effect of radioiodination on the biological properties of rituximab.
|
|
pubmed:affiliation |
Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute/Slotervaart Hospital, Amsterdam, The Netherlands.
|
|
pubmed:publicationType |
Journal Article,
Case Reports
|
